5:39 PM
 | 
Oct 25, 2011
 |  BC Extra  |  Company News

Amsterdam Molecular discontinues Glybera

Amsterdam Molecular Therapeutics Holding N.V. (Euronext:AMT) discontinued development of Glybera following last week's second CHMP decision against approval of the product in the EU for lipoprotein lipase (LPL) deficiency. The company will also reduce headcount by...

Read the full 172 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >